Ozoralizumab

Ozoralizumab is a monoclonal antibody designed for the treatment of rheumatoid arthritis. It is developed by Ablynx, a subsidiary of Sanofi. Ozoralizumab is a Nanobody, a type of antibody that is significantly smaller than conventional antibodies. This allows it to penetrate tissues more effectively and bind to its target with high specificity and affinity.

Mechanism of Action

Ozoralizumab works by binding to tumor necrosis factor alpha (TNFα), a protein that plays a key role in the inflammatory process of rheumatoid arthritis. By blocking the action of TNFα, ozoralizumab can reduce inflammation and slow the progression of the disease.

Clinical Trials

Ozoralizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. The results showed that the drug was well tolerated and had a significant effect on reducing the signs and symptoms of the disease.

Potential Side Effects

As with all medications, ozoralizumab may cause side effects. These can include nausea, headache, and fatigue. More serious side effects can include infection due to the suppression of the immune system.

See Also

• Rheumatoid arthritis
• Monoclonal antibody
• Tumor necrosis factor alpha

References

Ozoralizumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski